Double-blinded, placebo-controlled, randomized gene therapy using surgery for vector delivery

Human Gene Therapy

Volumn 23, Issue 5, 2012, Pages 438-441

  Crystal, Ronald G ^a   Kaminsky, Stephen M ^a   Hackett, Neil R ^a   Rosengart, Todd K ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; PLACEBO; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN 121; VASCULOTROPIN 165; VASCULOTROPIN 189;

ADENOVIRUS 5; ANGIOGENESIS; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; CORONARY STENT; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EXERCISE TEST; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; HEART CATHETERIZATION; HUMAN; MAXIMUM TOLERATED DOSE; MINITHORACOTOMY; NEUROSURGERY; NONHUMAN; NOTE; PHENOTYPE; POSTOPERATIVE COMPLICATION; POSTOPERATIVE DISCOMFORT; POSTOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIAL (TOPIC); RNA SPLICING; STUDY DESIGN; SURVIVAL RATE; THORACOTOMY; TRANSGENE; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; CORONARY ARTERY DISEASE; DOUBLE-BLIND METHOD; GENE THERAPY; GENETIC VECTORS; HUMANS; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURGICAL PROCEDURES, OPERATIVE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84861694218     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2012.062     Document Type: Note

References (33)

1. Allen, K.B., Dowling, R.D., Angell, W.W., et al. (2004). Transmyocardial revascularization: 5-year follow-up of a prospective, randomized multicenter trial. Ann. Thorac. Surg. 77, 1228-1234. (Pubitemid 38452353)
2. Amano, H., Hackett, N.R., Kaner, R.J., et al. (2005). Alteration of splicing signals in a genomic/cDNA hybrid VEGF gene to modify the ratio of expressed VEGF isoforms enhances safety of angiogenic gene therapy. Mol. Ther. 12, 716-724. (Pubitemid 41350153)
3. Arkin, L.M., Sondhi, D., Worgall, S., et al. (2005). Confronting the issues of therapeutic misconception, enrollment decisions, and personal motives in genetic medicine-based clinical research studies for fatal disorders. Hum. Gene Ther. 16, 1028-1036. (Pubitemid 41324562)
4. Bostick, N.A., Sade, R., Levine, M.A., et al. (2008). Placebo use in clinical practice: report of the American Medical Association Council on Ethical and Judicial Affairs. J. Clin. Ethics 19, 58-61.
5. Campeau, L. (1976). Letter: Grading of angina pectoris. Circulation 54, 522-523.
6. Chu, V., Kuang, J., McGinn, A., et al. (1999). Angiogenic response induced by mechanical transmyocardial revascularization. J. Thorac. Cardiovasc. Surg. 118, 849-856. (Pubitemid 29511067)
7. Crystal, R.G., Harvey, B.G.,Wisnivesky, J.P., et al. (2002). Analysis of risk factors for local delivery of low-and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions. Hum. Gene Ther. 13, 65-100. (Pubitemid 34075173)
8. Dekkers, W., and Boer, G. (2001). Sham neurosurgery in patients with Parkinson's disease: is it morally acceptable? J. Med. Ethics 27, 151-156. (Pubitemid 32982844)
9. Finniss, D.G.,Kaptchuk, T.J.,Miller, F., et al. (2010). Biological, clinical, and ethical advances of placebo effects. Lancet 375, 686-695.
10. Freed, C.R., Greene, P.E., Breeze, R.E., et al. (2001). Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N. Engl. J. Med. 344, 710-719. (Pubitemid 32204988)
11. Gitay-Goren, H., Soker, S., Vlodavsky, I., et al. (1992). The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. J. Biol. Chem. 267, 6093-6098.
12. Gyongyosi, M., Khorsand, A., Zamini, S., et al. (2005). NOGAguided analysis of regional myocardial perfusion abnormalities treated with intramyocardial injections of plasmid encoding vascular endothelial growth factor A-165 in patients with chronic myocardial ischemia: subanalysis of the EUROINJECT-ONE multicenter double-blind randomized study. Circulation 112, I157-I165. (Pubitemid 41266668)
13. Hackett, N.R., El Sawy, T., Lee, L.Y., et al. (2000). Use of quantitative TaqMan real-time PCR to track the time-dependent distribution of gene transfer vectors in vivo. Mol. Ther. 2, 649-656.
14. Harvey, B.G., Worgall, S., Ely, S., et al. (1999). Cellular immune responses of healthy individuals to intradermal administration of an E1-E3-adenovirus gene transfer vector. Hum. Gene Ther. 10, 2823-2837.
15. Lee, L.Y., Patel, S.R., Hackett, N.R., et al. (2000). Focal angiogen therapy using intramyocardial delivery of an adenovirus vector coding for vascular endothelial growth factor 121. Ann. Thorac. Surg. 69, 14-23.
16. Moldovan, N.I., Goldschmidt-Clermont, P.J., Parker-Thornburg, J., et al. (2000). Contribution of monocytes/macrophages to compensatory neovascularization: the drilling of metalloelastase-positive tunnels in ischemic myocardium. Circ. Res. 87, 378-384.
17. Moseley, J.B., O'Malley, K., Petersen, N.J., et al. (2002). A controlled trial of arthroscopic surgery for osteoarthritis of the knee. N. Engl. J. Med. 347, 81-88. (Pubitemid 34753477)
18. Nathwani, A.C., Tuddenham, E.G., Rangarajan, S., et al. (2011). Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med. 365, 2357-2365.
19. National Cancer Institute. Surveillance, epidemiology and end results, NCI (2011). www.seer.cancer.gov [last accessed March 20, 2012].
20. Park, J.E., Keller, G.A., and Ferrara, N. (1993). The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF.Mol. Biol. Cell 4, 1317-1326. (Pubitemid 24045761)
21. Pelletier, M.P., Giaid, A., Sivaraman, S., et al. (1998). Angiogenesis and growth factor expression in a model of transmyocardial revascularization. Ann. Thorac. Surg. 66, 12-18. (Pubitemid 28389224)
22. Poltorak, Z., Cohen, T., Sivan, R., et al. (1997). VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J. Biol. Chem. 272, 7151-7158. (Pubitemid 27166421)
23. Raper, S.E., Chirmule, N., Lee, F.S., et al. (2003). Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab. 80, 148-158. (Pubitemid 37272241)
24. Rosengart, T.K., Lee, L.Y., Patel, S.R., et al. (1999). Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 100, 468-474. (Pubitemid 29360154)
25. Schnell, M.A., Zhang, Y., Tazelaar, J., et al. (2001). Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol. Ther. 3, 708-722. (Pubitemid 32509868)
26. Schulz, K.F., Altman, D.G., and Moher, D. (2010). CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 340, c332.
27. Soker, S., Takashima, S., Miao, H.Q., et al. (1998). Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92, 735-745. (Pubitemid 28155313)
28. Squadrito, M.L. and De Palma, M. (2011). Macrophage regulation of tumor angiogenesis: implications for cancer therapy. Mol. Aspects Med. 32, 123-145.
29. Stewart, D.J., Hilton, J.D., Arnold, J.M., et al. (2006). Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of Ad-VEGF121 (AdVEGF121) versus maximum medical treatment. Gene Ther. 13, 1503-1511. (Pubitemid 44574158)
30. Stewart, D.J., Kutryk, M.J., Fitchett, D., et al. (2009). VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial. Mol. Ther. 17, 1109-1115.
31. Uberla, K.K. (1981). Randomized clinical trials: why not? Control. Clin. Trials 1, 295-303.
32. Whitlock, P.R., Hackett, N.R., Leopold, P.L., et al. (2004). Adenovirus-mediated transfer of a minigene expressing multiple isoforms of VEGF is more effective at inducing angiogenesis than comparable vectors expressing individual VEGF cDNAs. Mol. Ther. 9, 67-75. (Pubitemid 38208329)
33. Zachary, I., and Morgan, R.D. (2011). Therapeutic angiogenesis for cardiovascular disease: biological context, challenges, prospects. Heart 97, 181-189.